相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status
Nanae Horisawa et al.
BREAST CANCER (2022)
Prognostic and biologic significance of HER2-low expression in early breast cancer
P. Tarantino et al.
ANNALS OF ONCOLOGY (2022)
Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study
S. A. Hurvitz et al.
ANNALS OF ONCOLOGY (2022)
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Francesco Schettini et al.
NPJ BREAST CANCER (2021)
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status
Alexander Hein et al.
EUROPEAN JOURNAL OF CANCER (2021)
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
Carsten Denkert et al.
LANCET ONCOLOGY (2021)
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
Simon Peter Gampenrieder et al.
BREAST CANCER RESEARCH (2021)
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+or 2+
Louis Fehrenbacher et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Paolo Tarantino et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Gabriel Rinnerthaler et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The REDCap consortium: Building an international community of software platform partners
Paul A. Harris et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2019)
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Udai Banerji et al.
LANCET ONCOLOGY (2019)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes
Valeriy Domenyuk et al.
NATURE COMMUNICATIONS (2018)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer
Holm Eggemann et al.
ENDOCRINE-RELATED CANCER (2015)
Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer
Valentina Rossi et al.
ONCOLOGIST (2012)
Variable selection by ensembles for the Cox
Mu Zhu et al.
JOURNAL OF STATISTICAL COMPUTATION AND SIMULATION (2011)
Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support
Paul A. Harris et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2009)
HER-2/neu in breast cancer:: Interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization
TA Thomson et al.
MODERN PATHOLOGY (2001)
分享论文
